A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

ABSTRACT:

Objectives

To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.

Design

Double-blind, randomized, placebo-controlled trial.

Setting

Multicenter outpatient trial.

Participants

Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.

Intervention

Latrepirdine, 20 mg 3 times daily (n = 46), or matching placebo (n = 45) for a 90-day treatment period.

Main outcome measures

The primary outcome variable was tolerability, defined as the ability to complete the study at the assigned drug dosage. Secondary outcome variables included score changes from baseline to day 90 on the Unified Huntington

SUBMITTER: Kieburtz K 

PROVIDER: S-EPMC4134015 | biostudies-literature | 2010 Feb

REPOSITORIES: biostudies-literature